Hypertension Canada’s 2016 Canadian Hypertension Education Program guidelines for pharmacists

The Canadian Hypertension Education Program (CHEP) has been preparing and publishing guidelines for diagnosis and management of hypertension since 1999.1 The 2016 guidelines,2 released earlier this year, mark the 18th yearly production and update of evidence to date in the area of hypertension. Those guidelines, among other Hypertension Canada activities, can be considered as major contributors to the high levels of awareness and control of hypertension in Canada.3,4 Indeed, it has been reported that Canada has higher levels of awareness, treatment and control and lower prevalence of hypertension when compared with the United States and England.3

[1]  B. Hemmelgarn,et al.  The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial. , 2016, Journal of the American College of Cardiology.

[2]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[3]  P. McFarlane,et al.  Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. , 2016, The Canadian journal of cardiology.

[4]  F. McAlister,et al.  Epidemiology of Hypertension in Canada: An Update. , 2016, The Canadian journal of cardiology.

[5]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[6]  M. Woodward,et al.  Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis , 2016, The Lancet.

[7]  K. Tu,et al.  Thresholds for Diagnosing Hypertension Based on Automated Office Blood Pressure Measurements and Cardiovascular Risk , 2015, Hypertension.

[8]  D. Brouillard,et al.  Automated office blood pressure – being alone and not location is what matters most , 2015, Blood pressure monitoring.

[9]  R. Townsend,et al.  Comparison of an in-pharmacy automated blood pressure kiosk to daytime ambulatory blood pressure in hypertensive subjects. , 2015, Journal of the American Society of Hypertension : JASH.

[10]  F. McAlister,et al.  Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION) , 2014, Circulation.

[11]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[12]  S. Bangalore,et al.  Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III) , 2014, Circulation.

[13]  R. Tsuyuki,et al.  The 2014 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists , 2014, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[14]  B. Klop,et al.  The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view. , 2014, Atherosclerosis.

[15]  M. Burnier,et al.  Improving Blood Pressure Control Through Pharmacist Interventions: A Meta‐Analysis of Randomized Controlled Trials , 2014, Journal of the American Heart Association.

[16]  M. Myers Eliminating the Human Factor in Office Blood Pressure Measurement , 2014, Journal of clinical hypertension.

[17]  R Perera,et al.  Telephone counselling for smoking cessation. , 2013, The Cochrane database of systematic reviews.

[18]  F. McAlister,et al.  Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study , 2013, BMJ Open.

[19]  Simon L Bacon,et al.  The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. , 2013, The Canadian journal of cardiology.

[20]  R. Tsuyuki,et al.  The 2015 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists , 2013, Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC.

[21]  R. Tsuyuki,et al.  The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists , 2013, Canadian Pharmacists Journal / Revue des Pharmaciens du Canada.

[22]  Lee Hooper,et al.  Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses , 2013, BMJ : British Medical Journal.

[23]  L. Chambers,et al.  Comparison of blood pressure measurements using an automated blood pressure device in community pharmacies and family physicians' offices: a randomized controlled trial. , 2013, CMAJ open.

[24]  C. Naugler,et al.  Fasting time and lipid levels in a community-based population: a cross-sectional study. , 2012, Archives of internal medicine.

[25]  A. Khera,et al.  Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". , 2012, Archives of internal medicine.

[26]  Valérie Santschi,et al.  Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes , 2012, Diabetes Care.

[27]  M. Myers The great myth of office blood pressure measurement. , 2012, Journal of hypertension.

[28]  G. Kolyvas,et al.  Automated office blood pressure is associated with urine albumin excretion in hypertensive subjects. , 2012, American journal of hypertension.

[29]  M. Godwin,et al.  Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. , 2012, Family practice.

[30]  R. Moineddin,et al.  Where should automated blood pressure measurements be taken? Pilot RCT of BpTRU measurements taken in private or nonprivate areas of a primary care office , 2012, Blood pressure monitoring.

[31]  M. Tremblay,et al.  Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. , 2012, The Canadian journal of cardiology.

[32]  J. Tardif,et al.  Determinants of masked hypertension in hypertensive patients treated in a primary care setting , 2012, Internal medicine journal.

[33]  R. Tsuyuki,et al.  The Canadian Hypertension Education Program (CHEP) 2011 Guidelines for Pharmacists , 2011 .

[34]  B. Burnand,et al.  Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. , 2011, Archives of internal medicine.

[35]  E. Andreadis,et al.  Automated office blood pressure and 24-h ambulatory measurements are equally associated with left ventricular mass index. , 2011, American journal of hypertension.

[36]  S. Aldasouqi,et al.  Hypoglycemia in Patients With Diabetes on Antidiabetic Medications Who Fast for Laboratory Tests , 2011, Diabetes Care.

[37]  Michelle E. Kho,et al.  AGREE II: advancing guideline development, reporting and evaluation in health care , 2010, Canadian Medical Association Journal.

[38]  J. Graff Zivin,et al.  US Pharmacists' Effect as Team Members on Patient Care: Systematic Review and Meta-Analyses , 2010, Medical care.

[39]  Martin G Myers,et al.  A proposed algorithm for diagnosing hypertension using automated office blood pressure measurement , 2010, Journal of hypertension.

[40]  Martin G Myers,et al.  Measurement of blood pressure in the office: recognizing the problem and proposing the solution. , 2010, Hypertension.

[41]  A. Kiss,et al.  Consistent relationship between automated office blood pressure recorded in different settings , 2009, Blood pressure monitoring.

[42]  A. Kiss,et al.  Use of automated office blood pressure measurement to reduce the white coat response , 2009, Journal of hypertension.

[43]  B. Nordestgaard,et al.  Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.

[44]  P. Ridker,et al.  Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. , 2007, JAMA.

[45]  M. Godwin,et al.  Automated Measurement of Blood Pressure in Routine Clinical Practice , 2007, Journal of clinical hypertension.

[46]  E. Lonn,et al.  Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima–medial thickness in male firefighters , 2007, Journal of Human Hypertension.

[47]  Yutaka Imai,et al.  Prognosis of "masked" hypertension and "white-coat" hypertension detected by 24-h ambulatory blood pressure monitoring 10-year follow-up from the Ohasama study. , 2005, Journal of the American College of Cardiology.

[48]  C. Pepine,et al.  A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the international verapamil-trandolapril study (INVEST): a randomized controlled trial , 2004 .

[49]  Lawrence A Leiter,et al.  Lifestyle modifications to prevent and control hypertension. 1. Methods and an overview of the Canadian recommendations. Canadian Hypertension Society, Canadian Coalition for High Blood Pressure Prevention and Control, Laboratory Centre for Disease Control at Health Canada, Heart and Stroke Foundati , 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[50]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[51]  C. Held,et al.  Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS) , 1996, European heart journal.

[52]  C. Joyner,et al.  Prevalence of white coat effect in treated hypertensive patients in the community. , 1995, American journal of hypertension.

[53]  B. Hemmelgarn,et al.  Effectiveness of Community Pharmacist Prescribing and Care on Cardiovascular Risk Reduction: Randomized Controlled RxEACH Trial , 2016 .

[54]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[55]  Impact of Community Pharmacist Interventions in Hypertension Management on Patient Outcomes : A Randomized Controlled Trial , 2014 .

[56]  A. Khera,et al.  Fasting for lipid testing: Is it worth the trouble? , 2012, Archives of internal medicine.

[57]  W. J. Elliott,et al.  Conventional versus automated measurement of blood pressure in primary care patients with systolic hypertension: randomised parallel design controlled trial , 2012 .

[58]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[59]  L. Coupal,et al.  Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study , 2008, Journal of General Internal Medicine.

[60]  N. Campbell The Canadian Hypertension Education Program (CHEP)--a therapeutic knowledge translation program. , 2006, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[61]  T. Lancaster,et al.  Workplace interventions for smoking cessation. , 2003, The Cochrane database of systematic reviews.

[62]  T. Pickering,et al.  Masked hypertension. , 2002, Hypertension.

[63]  K. Fox,et al.  Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. , 1996, European heart journal.

[64]  Guidelines for pharmacists performing product selection. , 1990, American Pharmacy.